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INVITED EDITORIAL
A review of the randomized clinical trials of
adjuvant trastuzumab in human epidermal growth fac-
tor receptor (HER2)–positive breast cancer demonstrates
the great benefit of this monoclonal antibody whose po-
tential cardiotoxicity is a fascinating problem for the
cardiologist 1. The direct cardiotoxicity of trastuzumab,
a relatively new cardiomyopathy, is actually quite lim-
ited in the absence of prior anthracycline exposure. Con-
current blockage of the HER2 cardiac receptor is believed
to make repair of myocardial damage more difficult 2,3,
but this effect varies substantially from patient to pa-
tient. It is unpredictable, it does not appear to be dose-
dependent, and it is reversible. About 80% of patients
receiving trastuzumab as adjuvant treatment will main-
tain a normal left ventricular ejection fraction (LVEF),
and therefore questions naturally arise about how other-
wise to monitor for potential cardiotoxicity.
Cardiac injury can occur in the absence of systolic
dysfunction. The LVEF measurement can vary from
centre to centre (different methods could be used) and
even throughout the day by up to 10% in individual
patients—a level of fall that could result in treatment
being inappropriately suspended. To complicate mat-
ters further, the definition of cardiotoxicity as measured
by LVEF can vary substantially among clinical studies,
as can stoppage rules 4. Fortunately, the risk of severe
cardiotoxicity remains rare (0.6%–4%), and if such a
complication occurs, cessation of trastuzumab therapy
can often be followed by contractile improvement given
conventional treatment for heart failure. The demon-
strable recovery of LVEF can even allow for reintroduc-
tion of trastuzumab if the cancer prognosis demands it.
The management of an asymptomatic drop of LVEF
is difficult to define. In 14.2% of patients treated with
trastuzumab (as in the B-31 N 9831 trial), an asymp-
tomatic LVEF drop triggered stoppage of treatment.
In the HERA (Herceptin a Adjuvant) trial, in which
trastu-zumab was given sequentially, and in the
subgroup without anthracycline exposure of the Breast
Cancer International Research Group (BCIRG) 006 trial,
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a significantly lesser drop in LVEF was observed 6.
However, from a cardiologist’s viewpoint, a drop in
LVEF—reversible and symptomatic or not—is always
an issue, because it implies an effect on cardiac
contractility and actual intracellular damage (and there-
fore risk of cell death). Furthermore, previous damage
caused by anthracyclines is often permanent and sig-
nificant; the B 31-N9831 showed that 6% of patients
who had undergone previous adjuvant anthracycline
treatment were unable to begin trastuzumab because
of a baseline LVEF that was too low 7.
The reversible effect of the decrease in LVEF of-
ten observed with trastuzumab is disputable. Although
it is true that most patients improve once treatment is
stopped, many patients need specific cardiac care to
achieve that improvement, and many do not regain their
initial LVEF value.
When encountering a significant asymptomatic
drop in LVEF, and after appropriate stoppage of trastu-
zumab 6, some physicians, faced with lack of
randomized data on the subject, will wait for sponta-
neous improvement without a specific cardiac inter-
vention. Others will recommend interventions such as
angiotensin converting-enzyme inhibitors in a some-
what accelerated mode, as in any other cardiomyopa-
thy or situation of cardioprotection 6. An ongoing
dialogue between the cardiologist and the oncologist is
then important to maximize care of the patient!
Now that the benefits of trastuzumab are well es-
tablished, it is tempting to use this agent to treat pa-
tients with prior cardiac problems. However, the effect
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of trastuzumab on those patients (typically excluded
from the defining clinical studies) remains unclear. Ac-
cordingly, such patients should be very closely monitored.
The treating physicians must take the lack of knowl-
edge concerning the long-term effects of trastuzumab
into consideration, even more so when anthracyclines
are part of the equation. Younger patients undergoing
trastuzumab adjuvant therapy are obviously at risk from
other cardiac stresses in later life and will need car-
diac reserve, but it is reassuring that the B 31 and HERA
studies showed a stable rate of severe cardiotoxicity at
3 years of follow-up.
Given the impact of trastuzumab, cardiologists could
rightly question why an alternative to prior anthracycline
treatment could not be offered, especially to patients
who already have cardiac disease. Is the use of
anthracyclines as adjuvant therapy in HER2-positive
breast cancer still justified? The much-awaited results
of BCIRG 006 could help to answer that crucial question.
REFERENCES
1. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analy-
sis of doxorubicin and cyclophosphamide followed by paclitaxel
with or without trastuzumab in the North Central Cancer Treat-
ment Group N9831 adjuvant breast cancer trial. J Clin Oncol
2008;26:1231–8.
2. Chien KR. Herceptin and the heart—a molecular modifier of
cardiac failure. N Engl J Med 2006;354:789–90.
3. Liu X, Gu X, Li Z, et al. Neuregulin-1/erbB-activation im-
proves cardiac function and survival in models of ischemic,
dilated, and viral cardiomyopathy. J Am Coll Cardiol
2006;48:1438–47.
4. Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-
related cardiotoxicity: calling into question the concept of re-
versibility. J Clin Oncol 2007;25:3525–33.
5. Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of
trastuzumab-related cardiotoxicity: new insights based on clini-
cal course and response to medical treatment. J Clin Oncol
2005;23:7820–6
6. Mackey JR, Clemons M, Côté MA, et al. Cardiac management
during adjuvant trastuzumab therapy: recommendations of the
Canadian Trastuzumab Working Group. Curr Oncol
2008;15:24–35.
7. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus
adjuvant chemotherapy for operable HER2-positive breast can-
cer. N Engl J Med 2005;353:1673–84.